Skip to content
OpenCapital
Get started

Maravai LifeSciences Holdings, Inc. MRVI Cygnus — Revenue

Similar metrics at other companies

Certara, Inc. logo
CERTReportable Segment — Revenue
$106.92M+0.9%
Qorvo logo
QRVOCSG — Revenue
$93.28M-7.9%
AMP
AMPHPharmaceutical Products — Revenue
$171.17M+0.4%
Ashland logo
ASHLife Sciences — Revenue
$172M0.0%
Fortrea Holdings Inc. logo
FTREClinical Services Segment — Revenue
$636.5M-2.3%
Idexx Laboratories logo
IDXXCAG segment revenue — Total Revenue
$1.14B+14.3%

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$849.64M+204%
Enterprise value$954.59M+198%
P/S4.2×+3.0×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%—

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s cygnus — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s cygnus — revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — revenue of $18.36M in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s cygnus — revenue changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s cygnus — revenue increased by 1.4% year-over-year, from $18.1M to $18.36M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s cygnus — revenue?
Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s cygnus — revenue has grown at a -0.9% compound annual growth rate (CAGR), from $68.42M to $65.96M.
What does cygnus — revenue mean?
Represents the total gross income generated by the Biologics Safety Testing business segment through the sale of products and services. This metric reflects the market demand for safety testing solutions used in the development of drug therapies and vaccines. It serves as a primary indicator of the segment's commercial performance and market penetration.